Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 3
2007 1
2009 2
2010 6
2011 7
2012 11
2013 13
2014 8
2015 3
2016 3
2017 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis-a proof of principle and exploratory trial: is dose tapering practical in good responders?
Ibrahim F, Lorente-Cánovas B, Doré CJ, Bosworth A, Ma MH, Galloway JB, Cope AP, Pande I, Walker D, Scott DL. Ibrahim F, et al. Rheumatology (Oxford). 2017 Nov 1;56(11):2004-2014. doi: 10.1093/rheumatology/kex315. Rheumatology (Oxford). 2017. PMID: 28968858 Free PMC article. Clinical Trial.
Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial.
Cohen H, Hunt BJ, Efthymiou M, Arachchillage DR, Mackie IJ, Clawson S, Sylvestre Y, Machin SJ, Bertolaccini ML, Ruiz-Castellano M, Muirhead N, Doré CJ, Khamashta M, Isenberg DA; RAPS trial investigators. Cohen H, et al. Lancet Haematol. 2016 Sep;3(9):e426-36. doi: 10.1016/S2352-3026(16)30079-5. Lancet Haematol. 2016. PMID: 27570089 Free PMC article. Clinical Trial.
Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE.
Cohen H, Doré CJ, Clawson S, Hunt BJ, Isenberg D, Khamashta M, Muirhead N; RAPS Trial Protocol Collaborators. Cohen H, et al. Lupus. 2015 Sep;24(10):1087-94. doi: 10.1177/0961203315581207. Epub 2015 May 4. Lupus. 2015. PMID: 25940537 Free PMC article. Clinical Trial.
Second-line agents in myositis: 1-year factorial trial of additional immunosuppression in patients who have partially responded to steroids.
Ibrahim F, Choy E, Gordon P, Doré CJ, Hakim A, Kitas G, Isenberg D, Griffiths B, Lecky B, Chakravarty K, Winer J, Danko K, Cooper RG, White-Alao B, Scott DL. Ibrahim F, et al. Rheumatology (Oxford). 2015 Jun;54(6):1050-5. doi: 10.1093/rheumatology/keu442. Epub 2014 Nov 27. Rheumatology (Oxford). 2015. PMID: 25433040 Free PMC article. Clinical Trial.
Assessment of osteoarthritis candidate genes in a meta-analysis of nine genome-wide association studies.
Rodriguez-Fontenla C, Calaza M, Evangelou E, Valdes AM, Arden N, Blanco FJ, Carr A, Chapman K, Deloukas P, Doherty M, Esko T, Garcés Aletá CM, Gomez-Reino Carnota JJ, Helgadottir H, Hofman A, Jonsdottir I, Kerkhof HJ, Kloppenburg M, McCaskie A, Ntzani EE, Ollier WE, Oreiro N, Panoutsopoulou K, Ralston SH, Ramos YF, Riancho JA, Rivadeneira F, Slagboom PE, Styrkarsdottir U, Thorsteinsdottir U, Thorleifsson G, Tsezou A, Uitterlinden AG, Wallis GA, Wilkinson JM, Zhai G, Zhu Y; arcOGEN Consortium; Felson DT, Ioannidis JP, Loughlin J, Metspalu A, Meulenbelt I, Stefansson K, van Meurs JB, Zeggini E, Spector TD, Gonzalez A. Rodriguez-Fontenla C, et al. Arthritis Rheumatol. 2014 Apr;66(4):940-9. doi: 10.1002/art.38300. Arthritis Rheumatol. 2014. PMID: 24757145 Free PMC article.
49 results